All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is delighted to present a visual abstract summarizing key preliminary data from a phase II trial (NCT02807558) investigating the safety and efficacy of tamibarotene combination therapy in newly diagnosed adult patients with acute myeloid leukemia who are unfit for intensive chemotherapy. Tamibarotene is an oral, selective retinoic acid receptor alpha (RARα) agonist that received orphan drug designation from the U.S. Food and Drug Administration (FDA) in 2017 and has been previously discussed on by the AML Hub. This study compared response rates and survival outcomes in patients who were RARA-positive to patients who were RARA-negative.
To download this visual abstract, click below.Download here
Tamibarotene as maintenance therapy for acute promyelocytic leukemia improved long-term relapse-free survival
Maintenance therapy with tamibarotene significantly decreased relapse in patients with newly diagnosed APL compared to ATRA
The FDA grants SY-1425 Orphan Drug Designation for the treatment of AML
The FDA granted Orphan Drug Designation to SY-1425 (tamibarotene) for the treatment of patients with AML.
Subscribe to get the best content related to AML delivered to your inbox